ストックスクリーナーアプリを入手
351.02
1.29%
-4.58
アフターアワーズ：
352.00
0.98
+0.28%
前日終値:
$355.60
開ける：
$357.46
24時間の取引高:
2.26M
Relative Volume:
0.80
時価総額：
$189.22B
収益：
$36.74B
当期純損益:
$7.71B
株価収益率:
24.66
EPS:
14.2333
ネットキャッシュフロー:
$8.10B
1週間 パフォーマンス:
+0.89%
1か月 パフォーマンス:
-6.50%
6か月 パフォーマンス:
+20.99%
1年 パフォーマンス:
+24.74%
1日の値動き範囲:
$349.75
$357.46
1週間の範囲:
$335.06
$359.44
52週間の値動き範囲:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
351.02 | 189.22B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Hold |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-01-20 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-05 | アップグレード | Erste Group | Hold → Buy |
| 2025-11-24 | 再開されました | Truist | Hold |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-03 | 再開されました | Raymond James | Mkt Perform |
| 2025-05-20 | 再開されました | Guggenheim | Neutral |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-14 | ダウングレード | Truist | Buy → Hold |
| 2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | アップグレード | Truist | Hold → Buy |
| 2023-10-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 再開されました | BofA Securities | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 繰り返されました | Truist | Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Underperform |
| 2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-09 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-09 | 繰り返されました | Jefferies | Buy |
| 2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 開始されました | Daiwa Securities | Buy |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | アップグレード | Truist | Hold → Buy |
| 2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | ダウングレード | Truist | Buy → Hold |
| 2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 再開されました | Guggenheim | Neutral |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-17 | 再開されました | Morgan Stanley | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
Kelsey Financial LLC Makes New $7.13 Million Investment in Amgen Inc. $AMGN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $527.74 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Robeco Institutional Asset Management B.V. Increases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by KG&L Capital Management LLC - MarketBeat
Curtis Advisory Group Adds Amgen Shares to Portfolio - National Today
Factory Mutual Insurance Trims Amgen Stake - National Today
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Clarity Wealth Advisors LLC Invests $3.91 Million in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Is It Time To Revisit Amgen (AMGN) After The Recent 4.6% Share Price Pullback - simplywall.st
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer | PharmExec - Pharmaceutical Executive
Amgen’s FORWARD II Gout Study: What a Less Frequent Krystexxa Schedule Could Mean for Investors - TipRanks
Amgen-Backed DLL3 Combo Trial Could Be A Game Changer For Zai Lab (ZLAB) - simplywall.st
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again - Yahoo! Finance Canada
Amgen’s lung cancer drug tarlatamab wins China approval - WTAQ
Amgen (NASDAQ:AMGN) Price Target Raised to $326.00 - MarketBeat
Amgen’s Tarlatamab Approved in China - Pharmaceutical Executive
NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap - Barchart
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart
OFI Invest Asset Management Increases Stake in Amgen - National Today
OFI Invest Asset Management Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Prime Capital Investment Advisors LLC Has $6.32 Million Stake in Amgen Inc. $AMGN - MarketBeat
Encompass Wealth Advisors Trims Amgen Stake by Over 50% - National Today
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033 - GlobeNewswire Inc.
Amgen's lung cancer drug tarlatamab wins China approval - Reuters
Encompass Wealth Advisors LLC Sells 3,010 Shares of Amgen Inc. $AMGN - MarketBeat
Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now? - Yahoo Finance
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
What Amgen (AMGN)'s TEPEZZA On‑Body Injector Phase 3 Results Mean For Shareholders - simplywall.st
Lobbying Update: $50,000 of TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Guggenheim Adjusts Amgen (AMGN) Price Target to $351, Maintains - GuruFocus
Investors heavily search Amgen Inc. (AMGN): Here is what you need to know - MSN
Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs (NASDAQ:AMGN) - Seeking Alpha
Guggenheim Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $351 - Moomoo
Guggenheim raises Amgen stock price target to $351 on product mix - Investing.com Canada
Amgen (AMGN) Stock: GLP-1 Drug MariTide Drives Analyst Optimism - CoinCentral
We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play. - Barron's
Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $350 - Moomoo
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha
Truist raises Amgen stock price target to $325 on revenue outlook - Investing.com
Amgen’s Tepezza On Body Injector Data Tests Thyroid Eye Disease Moat - simplywall.st
Is Amgen Stock Poised For A Rally? - Trefis
Cantor Fitzgerald maintains Amgen stock rating ahead of earnings - Investing.com
Amgen releases positive topline results from phase 3 trial of teprotumumab-trbw (TEPEZZA) - Ophthalmology Times
BIP Wealth LLC Boosts Amgen Stake by Over 800% - National Today
BIP Wealth LLC Acquires 8,785 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition - Yahoo Finance
Amgen Inc CEO Robert A. Bradway 2025 total compensation $24.7 million - marketscreener.com
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
Amgen Inc (AMGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
2.18%
0.21%
大文字化:
|
ボリューム (24 時間):